Induction of Broad Cross-Subtype-Specific HIV-1 Immune Responses by a Novel Multivalent HIV-1 Peptide Vaccine in Cynomolgus Macaques | Zendy

Ali Azizi | Zendy; David E. Anderson | Zendy; José V. Torres | Zendy; Andrei Ogrel | Zendy; Masoud Ghorbani | Zendy; Catalina Soare | Zendy; Paul Sandstrom | Zendy; Jocelyne Fournier | Zendy; Francisco DíazMitoma | Zendy

Open Access

Induction of Broad Cross-Subtype-Specific HIV-1 Immune Responses by a Novel Multivalent HIV-1 Peptide Vaccine in Cynomolgus Macaques

Author(s) -

Ali Azizi,

David E. Anderson,

José V. Torres,

Andrei Ogrel,

Masoud Ghorbani,

Catalina Soare,

Paul Sandstrom,

Jocelyne Fournier,

Francisco DíazMitoma

Publication year - 2008

Publication title -

the journal of immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.737

H-Index - 372

eISSN - 1550-6606

pISSN - 0022-1767

DOI - 10.4049/jimmunol.180.4.2174

Subject(s) - immunogenicity , hiv vaccine , immune system , heterologous , virology , biology , aids vaccines , immunology , immunity , human immunodeficiency virus (hiv) , antigen , macaque , potency , hiv antigens , simian immunodeficiency virus , peptide vaccine , antigenic variation , vaccine trial , epitope , genetics , viral disease , gene , in vitro , paleontology

One of the major obstacles in the design of an effective vaccine against HIV-1 is its antigenic variation, which results in viral escape from the immune system. Through a bioinformatics approach, we developed an innovative multivalent HIV-1 vaccine comprised of a pool of 176 lipidated and nonlipidated peptides representing variable regions of Env and Gag proteins. The potency and breadth of the candidate vaccine against a panel of HIV-1 subtypes was evaluated in nonhuman primate (cynomolgus macaques) and humanized mouse (HLA-A2.1) models. The results demonstrate strong immunogenicity with both breadth (humoral and cellular immunity) and depth (immune recognition of widely divergent viral sequences) against heterologous HIV-1 subtypes A-F.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research